NASDAQ · VCEL

Vericel Corporation

$45.32 +$0.27 (+0.60%) 1D After hours
Charting by TradingView

Key Metrics

$2.30B
Market cap
107.20×
P/E · TTM
$292.09M
Revenue · TTM
$21.46M
Net income
EPS · TTM $0.43
Dividend yield —
Free cash flow $47.49M
Beta · 1Y 1.03
EBITDA · TTM $34.23M
Gross margin 74.8%

Snapshot

Market cap$2.30B
Enterprise value—
Shares outstanding51.1M
52-wk range$28.95 – $48.75
Avg volume · 20D490.8K
Net cash —
Book value / share$7.14
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About Vericel Corporation
IPO dateFeb 4, 1997
Employees398

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E107.20
P/S7.88
P/FCF48.45
EV/EBITDA—
EV/Sales—
Graham №$8.31

Profitability

Gross 74.8%
Operating 7.6%
Net 7.3%
FCF 16.3%
ROE / ROIC 6.6% · —

Financial Health

Current ratio5.18
Quick ratio4.79
Debt / equity—
Debt / EBITDA —
Net cash —
Working capital$196.91M

Cash Flow · TTM

Operating CF $61.69M
Capex −$14.21M
Free cash flow $47.49M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

7 / 9
Strong fundamentals · 7 of 9 signals passing

Altman Z-Score

10.8
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$8.31 vs $45.32
Trades 5.5× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings